The IP is pioneering chimeric antigen receptor (CAR) technology to target Nucleolin (NCL) expressing T cells, and it has the ability to pinpoint NCL, an untapped antigen in cancer immunotherapy, for CAR-T cell targeting. By crafting CARs designed to target NCL and expressing them on T cells’ surface, this technology showcases promising anti-tumor activity against a spectrum of cancer types. At its current conceptual stage, proof-of-concept experiments have demonstrated successful targeting of breast cancers. Further endeavors are planned to validate the efficacy and specificity of CAR-T cells against numerous other cancers through meticulous in vitro and in vivo assays. Its innovative approach in targeting NCL broadens the horizons of cancer treatment, potentially diversifying the therapeutic options available to patients. The adaptable nature of CAR-T cells enables the targeting of various cancers, including breast, lung, brain cancer, myeloid, and lymphoid leukemia, among others.